ClinicalTrials.gg
Active, not recruitingNCT05923866Updated Oct 6, 2026Results posted

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

A Phase 2 interventional study of ONO-2808 and Placebo in Multiple System Atrophy (MSA), sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 35 sites in 2 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.

Enrollment
17th of 57
92 · median 35
Started
2023
with 4 others
Phase 2
17 of 90
2 open now
Primary completion
2025-09
later than 1 of 31 live
Registered
74th of 90
by date

Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 17th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 in phase 2, reaches primary completion later than 1 of the 31 other live ones, and was the 74th registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Multiple System Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

Read the detailed description

This study will consist of a core part, an extension part, and an additional extension part. The purpose of the core part is to evaluate 3 doses of ONO-2808 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) changes in clinical outcome assessments (COA) and biomarkers considered to be related to the pharmacodynamics and potential efficacy of ONO-2808. The purpose of the extension part and the additional extension part is to evaluate 3 doses of ONO-2808 in MSA patients, including: 1) safety and tolerability and 2) changes in COAs and biomarkers considered to be related to the pharmacodynamics and potential efficacy of ONO-2808.

03

Conditions studied

  • Multiple System Atrophy (MSA)
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients with a diagnosis of clinically-established or clinically-probable MSA according to the novel Movement Disorder Society (MDS) criteria for MSA diagnosis (2022), including patients with MSA of either subtype (MSA-P or MSA-C).
  2. Patients at the early stages of the disease, defined as a maximum of 5 years since the onset of one of the following symptoms associated with MSA:

    • Parkinsonism
    • Ataxia
    • Orthostatic hypotension and/or urinary dysfunction
  3. Patients with an anticipated survival of at least 3 years in the opinion of the Investigator.
  4. Patients who are able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps and then to turn around and walk at least another 10 steps. Use of assistive devices (e.g., walker or cane) is allowed.
  5. Ability to swallow oral medication and be willing to adhere to the study intervention regimen.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females.
  2. Patients with a clinically-significant or unstable medical or surgical condition other than MSA that, in the opinion of the Investigator, might preclude safe completion of the study or might affect the results of the study (e.g., pulmonary, cardiovascular [including bradyarrhythmia], macular edema, and significant renal or hepatic dysfunction).
  3. Neurological diseases/disorders other than MSA, such as Parkinson's disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, normal pressure hydrocephalus, pharmacological, or post-encephalitic parkinsonism.
  4. Patients with documented liver diseases or cirrhosis.
  5. Positive results at Screening for active viral infections that include positive (HIV), surface antigen (HBsAg) and hepatitis B core antibody, and virus (HCV).
  6. Patients with suicide ideation according to the Investigator's clinical judgment per the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening or who have made a suicide attempt in the 6 months before Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    ONO-2808 Arm

    Drug: ONO-2808

  • Placebo comparator
    Placebo Arm

    Drug: Placebo

Interventions

  • Oral administration of ONO-2808 at low, middle or high doses once daily for 24 weeks in the core part, for a total of 80 weeks including the extension part, and for up to an additional 72 weeks in the additional extension part

  • DrugPlacebo

    Oral administration of placebo once daily for 24 weeks in the core part and for a total of 32 weeks including the extension part; Transition to low-dose of ONO-2808 for remainder of the extension part until week 80 and for up to an additional 72 weeks in the additional extension part

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE. A serious adverse event (SAE) was an event that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was considered an important medical event.

    Time frame: From screening up to follow-up for the core part (up to Week 28)

  2. Incidence of TEAEs by Highest Severity

    A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment.

    Time frame: From screening up to follow-up for the core part (up to Week 28)

  3. Incidence of Study Treatment-related TEAEs by Highest Severity

    A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE.

    Time frame: From screening up to follow-up for the core part (up to Week 28)

Secondary outcomes

  1. Plasma Concentration of ONO-2808

    Descriptive summary statistics were calculated for ONO-2808 plasma concentrations, by dose level and time point.

    Time frame: Week 2, Week 8, Week 12, and Week 24

07

Results

Posted Oct 6, 2026

Participant flow

Core Part
Participant flow — Core Part
MilestonePlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Started23232323
Completed19181716
Not completed4567
Withdrew: Withdrawal by subject0100
Withdrew: Adverse event1235
Withdrew: Death0011
Withdrew: Physician decision1011
Withdrew: Non-complicance with study drug0100
Withdrew: Other2110
Extension Part (Ongoing)
Participant flow — Extension Part (Ongoing)
MilestonePlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Started0000
Completed0000
Not completed0000
Additional Extension Part (Ongoing)
Participant flow — Additional Extension Part (Ongoing)
MilestonePlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Started0000
Completed0000
Not completed0000

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE. A serious adverse event (SAE) was an event that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was considered an important medical event.

Time frame:
From screening up to follow-up for the core part (up to Week 28)
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Incidence of TEAEs21222121
Incidence of study treatment-related TEAEs75611
Incidence of TEAEs leading to withdrawal of study treatment1235
Incidence of study treatment-related TEAEs leading to withdrawal of study treatment1135
Incidence of TESAEs6444
Incidence of study treatment-related TESAEs1100
Incidence of TEAEs leading to death0011
Incidence of study treatment-related TEAEs leading to death0000
PrimaryIncidence of TEAEs by Highest Severity

A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment.

Time frame:
From screening up to follow-up for the core part (up to Week 28)
Reported as:
Count of participants · Participants
Incidence of TEAEs by Highest Severity
ParticipantsPlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Incidence of TEAEs21222121
Mild79126
Moderate99414
Severe5451
PrimaryIncidence of Study Treatment-related TEAEs by Highest Severity

A TEAE was defined as any adverse event occurring or worsening on or after the first dose of study treatment. A TEAE was considered study treatment-related if there was a reasonable causal relationship between study intervention administration and the TEAE.

Time frame:
From screening up to follow-up for the core part (up to Week 28)
Reported as:
Count of participants · Participants
Incidence of Study Treatment-related TEAEs by Highest Severity
ParticipantsPlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Incidence of Study Treatment-related TEAEs75611
Mild4434
Moderate2027
Severe1110
SecondaryPlasma Concentration of ONO-2808

Descriptive summary statistics were calculated for ONO-2808 plasma concentrations, by dose level and time point.

Time frame:
Week 2, Week 8, Week 12, and Week 24
Reported as:
Mean · ng/mL
Plasma Concentration of ONO-2808
ng/mLONO-2808 LowONO-2808 MiddleONO-2808 High
Week 2 (Before Daily Dose)186.6 ± 63.6378.2 ± 129.1612.7 ± 176.0
Week 8 (Before Daily Dose)207.9 ± 69.5396.4 ± 117.7780.0 ± 231.6
Week 12 (Before Daily Dose)202.4 ± 67.2409.4 ± 108.2851.4 ± 343.4
Week 12 (3h ± 1h Post Daily Dose)264.6 ± 86.3474.8 ± 118.41093.3 ± 373.4
Week 12 (5h ± 1h Post Daily Dose)267.1 ± 91.2492.3 ± 119.71201.2 ± 321.9
Week 24 (Before Daily Dose)220.0 ± 69.8395.0 ± 145.1778.9 ± 406.9
Week 24 (3h ± 1h Post Daily Dose)286.6 ± 89.7540.7 ± 152.51158.9 ± 326.0
Week 24 (5h ± 1h Post Daily Dose)284.8 ± 85.8556.4 ± 163.11116.2 ± 330.7

Adverse events

Collected over From screening up to follow-up for the core part (up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/23 (0%)6/23 (26.1%)21/23 (91.3%)
ONO-2808 Low0/23 (0%)4/23 (17.4%)22/23 (95.7%)
ONO-2808 Middle1/23 (4.3%)4/23 (17.4%)21/23 (91.3%)
ONO-2808 High1/23 (4.3%)4/23 (17.4%)21/23 (91.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
ConstipationGastrointestinal disorders0/230/230/231/23
BronchitisInfections and infestations0/230/231/230/23
PneumoniaInfections and infestations1/230/230/230/23
Pneumonia aspirationInfections and infestations0/231/230/230/23
Urinary tract infectionInfections and infestations0/230/231/230/23
FallInjury, poisoning and procedural complications1/230/230/230/23
Femoral neck fractureInjury, poisoning and procedural complications1/230/230/230/23
Shoulder fractureInjury, poisoning and procedural complications0/231/230/230/23
Blood creatine phosphokinase increasedInvestigations0/230/230/231/23
Transaminases increasedInvestigations0/231/230/230/23
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPlaceboONO-2808 LowONO-2808 MiddleONO-2808 High
Urinary tract infectionInfections and infestations8/239/232/234/23
HeadacheNervous system disorders0/233/232/236/23
ConstipationGastrointestinal disorders0/231/230/234/23
ContusionInjury, poisoning and procedural complications4/232/231/231/23
ArthralgiaMusculoskeletal and connective tissue disorders4/231/231/231/23
FallInjury, poisoning and procedural complications3/233/232/230/23
NasopharyngitisInfections and infestations1/230/232/233/23
FatigueGeneral disorders3/231/231/232/23
DizzinessNervous system disorders1/230/230/233/23
DiarrhoeaGastrointestinal disorders3/231/231/230/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
Median58.0 (51 to 76)63.0 (46 to 80)65.0 (54 to 74)60.0 (49 to 73)62.0 (46 to 80)
Age, Customized
Age, Customized(Participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
30-<50 years01012
50-<65 years1814101456
65-<75 years4613831
>=75 years12003
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
Female81491041
Male159141351
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
American Indian or Alaska Native10001
Asian739625
Native Hawaiian or Other Pacific Islander00000
Black or African American02125
White1518131561
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
United States1921152075
Japan428317
Years since Initial Diagnosis of Primary Disease
Years since Initial Diagnosis of Primary Disease(Participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
0-<1 year8610832
1-<2 years10106935
2-<3 years343212
3-<4 years223310
4-<5 years01113
Subtype of multiple system atrophy (MSA)
Subtype of multiple system atrophy (MSA)(Participants)PlaceboONO-2808 LowONO-2808 MiddleONO-2808 HighTotal
Likely MSA-P (Parkinsonian subtype of MSA)1311121248
Likely MSA-C (Cerebellar subtype of MSA)1012111144
08

Study locations

35 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Sep 2025, 23 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 28, 2023
StartActual
Sep 22, 2023
Primary completionActual
Sep 15, 2025
CompletionEst.
Oct 31, 2027
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
1 edited, 2 added, 8 removed
What changed in the outcomes
  • EditedIncidence and severity of treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs) and treatmentTreatment-emergent serious adverse eventsSerious Adverse Events (TESAEs)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164) → From screening up to follow-up for the core part (up to Week 28)
  • AddedIncidence of TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
  • AddedIncidence of Study Treatment-related TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
  • RemovedVital signs (blood pressure)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedVital signs (pulse rate)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedVital signs (temperature)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedVital signs (respiratory rate)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • Removed12-lead electrocardiograms (ECGs); parameters such as, but not limited to, heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedClinically-significant abnormal physical examination findingsTime frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedClinical laboratory abnormalities (hematology, clinical chemistry, and urinalysis)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
  • RemovedClinically-abnormal findings in the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
Oct 6, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPlasma concentrationConcentration of ONO-2808Time frame: Week 2, Week 8, Week 12, and Week 24
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Primary outcomes 1 edited, 2 added, 8 removed
    What changed in the outcomes
    • EditedIncidence and severity of treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs) and treatmentTreatment-emergent serious adverse eventsSerious Adverse Events (TESAEs)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164) → From screening up to follow-up for the core part (up to Week 28)
    • AddedIncidence of TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
    • AddedIncidence of Study Treatment-related TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
    • RemovedVital signs (blood pressure)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedVital signs (pulse rate)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedVital signs (temperature)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedVital signs (respiratory rate)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • Removed12-lead electrocardiograms (ECGs); parameters such as, but not limited to, heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedClinically-significant abnormal physical examination findingsTime frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedClinical laboratory abnormalities (hematology, clinical chemistry, and urinalysis)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    • RemovedClinically-abnormal findings in the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From screening up to follow-up for the core part, for the extension part, and for the additional extension part (up to Week 164)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPlasma concentrationConcentration of ONO-2808Time frame: Week 2, Week 8, Week 12, and Week 24
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05923866
Responsible party
Sponsor
First posted
Jun 28, 2023
Start date
Sep 22, 2023
Primary completion
Sep 15, 2025
Completion
Oct 31, 2027 (estimated)
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-2808

Start the discussion